Cribrostatin 6 induces death in cancer cells through a reactive oxygen species (ROS)-mediated mechanism

Investigational New Drugs

Volumn 29, Issue 4, 2011, Pages 562-573

  Hoyt, Mirth T ^a   Palchaudhuri, Rahul ^a   Hergenrother, Paul J ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Apoptosis; Cancer stem cells; Cribrostatin 6; Drug resistant cell lines; HMOX1; Quiescent 3T3; Quiescent cells; Quinone; ROS; Transcript profile

Indexed keywords

AMINOACRIDINE; CAMPTOTHECIN; CISPLATIN; CRIBROSTATIN 6; DOXORUBICIN; ETOPOSIDE; MITOMYCIN C; NATURAL PRODUCT; PACLITAXEL; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

3T3 CELLS; ACETYLCYSTEINE; ANIMALS; CAMPTOTHECIN; CELL CYCLE; CELL DEATH; CELL HYPOXIA; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOPROTECTION; DNA; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; ETHIDIUM; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEME OXYGENASE-1; HUMANS; ISOQUINOLINES; MICE; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; UP-REGULATION;

EID: 79959746342     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9390-x     Document Type: Article

References (75)

1. Tewey KM, Rowe TC, Yang L, Halligan BD, Liu LF (1984) Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science 226:466-468 (Pubitemid 14012819)
2. Begleiter A (1983) Cytocidal action of the quinone group and its relationship to antitumor activity. Cancer Res 43:481-484
3. Bolzan AD, Bianchi MS (2001) Genotoxicity of streptonigrin: a review. Mutat Res 488:25-37 (Pubitemid 32166781)
4. Li V-S, Choi D, Tang M, Kohn H (1996) Concerning in vitro mitomycin-DNA alkylation. J Am Chem Soc 118:3765-3766 (Pubitemid 26160414)
5. Le SB, Hailer MK, Buhrow S et al (2007) Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity. J Biol Chem 282:8860-8872 (Pubitemid 47093495)
6. Lu HR, Zhu H, Huang M et al (2005) Reactive oxygen species elicit apoptosis by concurrently disrupting topoisomerase II and DNA-dependent protein kinase. Mol Pharmacol 68:983-994 (Pubitemid 41345790)
7. Pelicano H, Carney D, Huang P (2004) ROS stress in cancer cells and therapeutic implications. Drug Resist Updat 7:97-110 (Pubitemid 38736063)
8. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT (2003) Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 73:2047-2058 (Pubitemid 36930039)
9. Swift LP, Rephaeli A, Nudelman A, Phillips DR, Cutts SM (2006) Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. Cancer Res 66:4863-4871
10. Coldwell KE, Cutts SM, Ognibene TJ, Henderson PT, Phillips DR (2008) Detection of adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant adriamycin concentrations. Nucleic Acids Res 36:e100
11. Belcourt MF, Penketh PG, Hodnick WF et al (1999) Mitomycin resistance in mammalian cells expressing the bacterial mitomycin C resistance protein MCRA. Proc Natl Acad Sci USA 96:10489-10494 (Pubitemid 29422586)
12. Pettit GR, Collins JC, Herald DL et al (1992) Isolation and structure of cribrostatins 1 and 2 from the blue marine sponge Cribrochalina sp. Can J Chem 70:1170-1175
13. Pettit GR, Collins JC, Knight JC et al (2003) Antineoplastic agents. 485. Isolation and structure of cribrostatin 6, a dark blue cancer cell growth inhibitor from the marine sponge Cribrochalina sp. J Nat Prod 66:544-547 (Pubitemid 36531908)
14. Pettit GR, Knight JC, Collins JC et al (2000) Antineoplastic agents 430. Isolation and structure of cribrostatins 3, 4, and 5 from the republic of maldives cribrochalina species. J Nat Prod 63:793-798 (Pubitemid 30452174)
15. Sandoval IT, Davis RA, Bugni TS, Concepcion GP, Harper MK, Ireland CM (2004) Cytotoxic isoquinoline quinones from sponges of the genus Petrosia. Nat Prod Res 18:89-93 (Pubitemid 38190213)
16. Nakahara S, Kubo A, Mikami Y, Ito J (2006) Synthesis of cribrostatin 6 and its related compounds. Heterocycles 68:515-520
17. Pettit RK, Fakoury BR, Knight JC et al (2004) Antibacterial activity of the marine sponge constituent cribrostatin 6. J Med Microbiol 53:61-65 (Pubitemid 38352404)
18. Nakahara S, Kubo A (2004) Synthesis of cribrostatin 6. Heterocycles 63:2355-2362
19. Nakahara S, Kubo A (2003) Catalytic hydrogenation of 8-acyloxy-1- cyanoisoquinoline and synthesis of 9-methoxy-9-deethoxy-cribrostatin 6. Heterocycles 60:2717-2725
20. Markey MD, Kelly TR (2008) Synthesis of cribrostatin 6. J Org Chem 73:7441-7443
21. Knueppel D, Martin SF (2009) Total synthesis of cribrostatin 6. Angew Chem Int Ed Engl 48:2569-2571
22. Vichai V, Kirtikara K (2006) Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 1:1112-1116
23. McGrath T, Center MS (1988) Mechanisms of multidrug resistance in HL60 cells: evidence that a surface membrane protein distinct from P-glycoprotein contributes to reduced cellular accumulation of drug. Cancer Res 48:3959-3963
24. Jackson RC (1989) The problem of the quiescent cancer cell. Adv Enzyme Regul 29:27-46
25. Jordan CT, Guzman ML, Noble M (2006) Cancer stem cells. N Engl J Med 355:1253-1261 (Pubitemid 44427449)
26. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284 (Pubitemid 40488633)
27. Horiatis D, Wang Q, Pinski J (2004) A new screening system for proliferation-independent anticancer agents. Cancer Lett 210:119-124 (Pubitemid 38692596)
28. Visvader JE, Lindeman GJ (2008) Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 8:755-768
29. Siu WY, Arooz T, Poon RY (1999) Differential responses of proliferating versus quiescent cells to adriamycin. Exp Cell Res 250:131-141 (Pubitemid 29391577)
30. Jainchill JL, Todaro GJ (1970) Stimulation of cell growth in vitro by serum with and without growth factor relation to contact inhibition and viral transformation. Exp Cell Res 59:137-146
31. Baguley BC, Falkenhaug EM (1978) The interaction of ethidium with synthetic double-stranded polynucleotides at low ionic strength. Nucleic Acids Res 5:161-171
32. Nitiss JL (2009) Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 9:338-350
33. Palchaudhuri R, Hergenrother PJ (2007) DNA as a target for anticancer compounds: methods to determine the mode of binding and the mechanism of action. Curr Opin Biotechnol 18:497-503
34. Pommier Y (2006) Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer 6:789-802
35. Hande KR (1998) Clinical applications of anticancer drugs targeted to topoisomerase II. Biochim Biophys Acta 1400:173-184
36. Bolognese A, Correale G, Manfra M, Esposito A, Novellino E, Lavecchia A (2008) Antitumor agents 6. Synthesis, structure-activity relationships, and biological evaluation of spiro[imidazolidine-4, 3′-thieno[2, 3-g]quinoline]-tetraones and spiro[thieno[2, 3-g]quinoline-3, 5′-[1, 2, 4]triazinane]-tetraones with potent antiproliferative activity. J Med Chem 51:8148-8157
37. Suzuki K, Yahara S, Kido Y, Nagao K, Hatano Y, Uyeda M (1998) Topostatin, a novel inhibitor of topoisomerases I and II produced by Thermomonospora alba strain No. 1520. II. Physicochemical properties and structure elucidation. J Antibiot (Tokyo) 51:999-1003
38. Yoshinari T, Yamada A, Uemura D et al (1993) Induction of topoisomerase I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res 53:490-494 (Pubitemid 23059425)
39. Chene P, Rudloff J, Schoepfer J et al (2009) Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue. BMC Chem Biol 9:1
40. Meng LH, Zhang JS, Ding J (2001) Salvicine, a novel DNA topoisomerase II inhibitor, exerting its effects by trapping enzyme-DNA cleavage complexes. Biochem Pharmacol 62:733-741
41. Park HJ, Lee HJ, Lee EJ et al (2003) Cytotoxicity and DNA topoisomerase inhibitory activity of benz[f]indole-4, 9-dione analogs. Biosci Biotechnol Biochem 67:1944-1949 (Pubitemid 39251716)
42. Tzu-Hao W, Hsin-Shih W, Yung-Kwei S (2000) Paclitaxel-induced cell death. Cancer 88:2619-2628
43. Jordan P, Carmo-Fonseca M (2000) Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci 57:1229-1235 (Pubitemid 30663480)
44. Tsao YP, D'Arpa P, Liu LF (1992) The involvement of active DNA synthesis in camptothecin-induced G2 arrest: altered regulation of p34cdc2/cyclin B. Cancer Res 52:1823-1829
45. Hsiang YH, Hertzberg R, Hecht S, Liu LF (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873-14878 (Pubitemid 16211028)
46. Ling YH, el-Naggar AK, Priebe W, Perez-Soler R (1996) Cell cycle-dependent cytotoxicity, G2/M phase arrest, and disruption of p34cdc2/cyclin B1 activity induced by doxorubicin in synchronized P388 cells. Mol Pharmacol 49:832-841
47. Kletsas D, Barbieri D, Stathakos D et al (1998) The highly reducing sugar 2-deoxy-D-ribose induces apoptosis in human fibroblasts by reduced glutathione depletion and cytoskeletal disruption. Biochem Biophys Res Commun 243:416-425 (Pubitemid 28414040)
48. Sheikh MS, Garcia M, Zhan Q, Liu Y, Fornace AJ Jr (1996) Cell cycle-independent regulation of p21Waf1/Cip1 and retinoblastoma protein during okadaic acid-induced apoptosis is coupled with induction of Bax protein in human breast carcinoma cells. Cell Growth Differ 7:1599-1607 (Pubitemid 26415155)
49. Durrant D, Richards JE, Walker WT, Baker KA, Simoni D, Lee RM (2008) Mechanism of cell death induced by cis-3, 4′, 5-trimethoxy-3′- aminostilbene in ovarian cancer. Gynecol Oncol 110:110-117
50. Criddle DN, Gillies S, Baumgartner-Wilson HK et al (2006) Menadione-induced reactive oxygen species generation via redox cycling promotes apoptosis of murine pancreatic acinar cells. J Biol Chem 281:40485-40492 (Pubitemid 46041851)
51. Kirshner JR, He S, Balasubramanyam V et al (2008) Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7:2319-2327
52. Place AE, Suh N, Williams CR et al (2003) The novel synthetic triterpenoid, CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 9:2798-2806 (Pubitemid 36842126)
53. Cervantes A, Pinedo HM, Lankelma J, Schuurhuis GJ (1988) The role of oxygen-derived free radicals in the cytotoxicity of doxorubicin in multidrug resistant and sensitive human ovarian cancer cells. Cancer Lett 41:169-177
54. Cathcart R, Schwiers E, Ames BN (1983) Detection of picomole levels of hydroperoxides using a fluorescent dichlorofluorescein assay. Anal Biochem 134:111-116 (Pubitemid 14231364)
55. Lamb J (2007) The connectivity map: a new tool for biomedical research. Nat Rev Cancer 7:54-60
56. Hieronymus H, Lamb J, Ross KN et al (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10:321-330 (Pubitemid 44512193)
57. Lamb J, Crawford ED, Peck D et al (2006) The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313:1929-1935 (Pubitemid 44497995)
58. Shibahara S (2003) The heme oxygenase dilemma in cellular homeostasis: new insights for the feedback regulation of heme catabolism. Tohoku J Exp Med 200:167-186
59. Pietsch EC, Chan JY, Torti FM, Torti SV (2003) Nrf2 mediates the induction of ferritin H in response to xenobiotics and cancer chemopreventive dithiolethiones. J Biol Chem 278:2361-2369 (Pubitemid 36801308)
60. Ferris CD, Jaffrey SR, Sawa A et al (1999) Haem oxygenase-1 prevents cell death by regulating cellular iron. Nat Cell Biol 1:152-157 (Pubitemid 129656019)
61. Nagai T, Kikuchi S, Ohmine K et al (2008) Hemin reduces cellular sensitivity to imatinib and anthracyclins via Nrf2. J Cell Biochem 104:680-691 (Pubitemid 351671654)
62. Brown JM (1993) SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170
63. Marcu L, Olver I (2006) Tirapazamine: from bench to clinical trials. Curr Clin Pharmacol 1:71-79
64. Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003) Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 60:6-20 (Pubitemid 36223114)
65. Matsunaga, T, Tsuji, Y, Kaai, K, et al (2010) Toxicity against gastric cancer cells by combined treatment with 5-fluorouracil and mitomycin c: implication in oxidative stress. Cancer Chemother Pharmacol. doi:10.1007/s00280-009-1292-5
66. Laux I, Nel A (2001) Evidence that oxidative stress-induced apoptosis by menadione involves Fas-dependent and Fas-independent pathways. Clin Immunol 101:335-344
67. Kang YH, Yi MJ, Kim MJ et al (2004) Caspase-independent cell death by arsenic trioxide in human cervical cancer cells: reactive oxygen species-mediated poly(ADP-ribose) polymerase-1 activation signals apoptosis-inducing factor release from mitochondria. Cancer Res 64:8960-8967
68. Lee CS, Park SY, Ko HH, Han ES (2004) Effect of change in cellular GSH levels on mitochondrial damage and cell viability loss due to mitomycin c in small cell lung cancer cells. Biochem Pharmacol 68:1857-1867 (Pubitemid 39278508)
69. Siu WY, Yam CH, Poon RYC (1999) G1 versus G2 cell cycle arrest after adriamycin-induced damage in mouse Swiss3T3 cells. FEBS Lett 461:299-305 (Pubitemid 29533351)
70. Matzno S, Yamaguchi Y, Akiyoshi T, Nakabayashi T, Matsuyama K (2008) An attempt to evaluate the effect of vitamin K3 using as an enhancer of anticancer agents. Biol Pharm Bull 31:1270-1273 (Pubitemid 351871173)
71. Emil Mladenov ITBA (2007) Activation of the S phase DNA damage checkpoint by mitomycin C. J Cell Physiol 211:468-476
72. Trachootham D, Alexandre J, Huang P (2009) Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov 8:579-591
73. Berkenblit A, Eder JP Jr, Ryan DP et al (2007) Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13:584-590 (Pubitemid 46225365)
74. Tuma RS (2008) Reactive oxygen species may have antitumor activity in metastatic melanoma. J Natl Cancer Inst 100:11-12
75. Hauschild A, Eggermont AM, Jacobson E, O'Day SJ (2009) Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM). J Clin Oncol (Meeting Abstracts) 27:LBA9012